JP7478142B2 - Ｓａｒｍ１阻害剤 - Google Patents

Ｓａｒｍ１阻害剤 Download PDF

Info

Publication number
JP7478142B2
JP7478142B2 JP2021518046A JP2021518046A JP7478142B2 JP 7478142 B2 JP7478142 B2 JP 7478142B2 JP 2021518046 A JP2021518046 A JP 2021518046A JP 2021518046 A JP2021518046 A JP 2021518046A JP 7478142 B2 JP7478142 B2 JP 7478142B2
Authority
JP
Japan
Prior art keywords
certain embodiments
disease
sarm1
compounds
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021518046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528488A5 (enExample
JP2021528488A (ja
Inventor
ロバート・オーエン・ヒューズ
ラジェシュ・デブラジ
トッド・ボサナック
リチャード・アンドリュー・ジャージェス－パイク
アンドリュー・サイモン・ブリアリー
ジョナサン・ベントリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Disarm Therapeutics Inc
Original Assignee
Disarm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Disarm Therapeutics Inc filed Critical Disarm Therapeutics Inc
Publication of JP2021528488A publication Critical patent/JP2021528488A/ja
Publication of JP2021528488A5 publication Critical patent/JP2021528488A5/ja
Application granted granted Critical
Publication of JP7478142B2 publication Critical patent/JP7478142B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2021518046A 2018-06-07 2019-06-06 Ｓａｒｍ１阻害剤 Active JP7478142B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682045P 2018-06-07 2018-06-07
US62/682,045 2018-06-07
PCT/US2019/035839 WO2019236884A1 (en) 2018-06-07 2019-06-06 Inhibitors of sarm1

Publications (3)

Publication Number Publication Date
JP2021528488A JP2021528488A (ja) 2021-10-21
JP2021528488A5 JP2021528488A5 (enExample) 2022-06-10
JP7478142B2 true JP7478142B2 (ja) 2024-05-02

Family

ID=68770684

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021518046A Active JP7478142B2 (ja) 2018-06-07 2019-06-06 Ｓａｒｍ１阻害剤

Country Status (7)

Country Link
US (1) US12448374B2 (enExample)
EP (1) EP3801499B1 (enExample)
JP (1) JP7478142B2 (enExample)
CN (1) CN112839648B (enExample)
ES (1) ES2988933T3 (enExample)
MA (1) MA52809A (enExample)
WO (1) WO2019236884A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3102645A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
EP3801503A4 (en) 2018-06-07 2021-12-08 Disarm Therapeutics, Inc. INHIBITORS OF SARM1
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
US12624025B2 (en) 2019-06-06 2026-05-12 Disarm Therapeutics, Inc. Inhibitors of SARM1
JP7319395B2 (ja) 2019-06-14 2023-08-01 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１の阻害剤
WO2021050913A1 (en) 2019-09-12 2021-03-18 Disarm Therapeutics, Inc. Inhibitors of sarm1
WO2021108602A1 (en) * 2019-11-26 2021-06-03 Disarm Therapeutics, Inc. Methods and compositions for neuroprotection
CA3174321A1 (en) 2020-04-09 2021-10-14 Disarm Therapeutics, Inc. Indazole derivatives as inhibitors of sarm1
WO2021207308A1 (en) * 2020-04-09 2021-10-14 Disarm Therapeutics, Inc. Condensed pyrazole derivatives as inhibitors of sarm1
TW202334117A (zh) * 2020-08-24 2023-09-01 美商達薩瑪治療公司 Ｓａｒｍ１之抑制劑
WO2024100421A1 (en) * 2022-11-12 2024-05-16 Cambridge Enterprise Limited Sarm1 inhibitors for use in therapy and cosmetics
CN121399112A (zh) * 2023-04-27 2026-01-23 维泰瑞隆有限公司 Sarm1调节剂、其制备和用途
CN116836162B (zh) * 2023-05-24 2025-09-05 南方医科大学 吡唑[4,3-c]吡啶类化合物或其药学上可接受的盐及其应用
WO2026086928A1 (en) * 2024-10-25 2026-04-30 Sironax Ltd. Sarm1 modulators, preparations, and uses thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080153828A1 (en) 2005-04-05 2008-06-26 Elizabeth Aaron Collins Imidazopyridazine Compounds
WO2009041567A1 (ja) 2007-09-27 2009-04-02 Banyu Pharmaceutical Co., Ltd. メラニン凝集ホルモン受容体拮抗作用を有するジアリールケチミン誘導体
JP2011530500A (ja) 2008-08-06 2011-12-22 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
WO2012106343A2 (en) 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
JP2013519681A (ja) 2010-02-11 2013-05-30 オーエスアイ・ファーマシューティカルズ，エルエルシー ７−アミノフロピリジン誘導体
JP2014509313A (ja) 2011-02-01 2014-04-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ７−アザインドール誘導体
WO2014198848A2 (en) 2013-06-12 2014-12-18 Lytix Biopharma As Compounds
WO2018011628A1 (en) 2016-07-11 2018-01-18 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2018071794A1 (en) 2016-10-14 2018-04-19 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA847926B (en) * 1983-10-17 1986-05-28 Lilly Co Eli 3-bicyclicpyridinium-methyl cephalosporins
US5468757A (en) * 1994-01-31 1995-11-21 Eli Lilly And Company 6-azaindole thromboxane synthase inhibitors
AU747776B2 (en) 1998-10-30 2002-05-23 Merck & Co., Inc. Thrombin inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
CA2443918C (en) 2001-04-11 2012-06-05 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents containing rho kinase inhibitors
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
CZ2004408A3 (cs) 2001-10-02 2005-03-16 Pharmacia & Upjohn Company Azabicyklicky substituované kondenzované heteroarylsloučeniny
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
ES2276048T3 (es) 2002-03-05 2007-06-16 Eli Lilly And Company Derivados de purina como inhibidores de cinasa.
CN1656079A (zh) 2002-05-31 2005-08-17 卫材株式会社 吡唑化合物和含有该化合物的药物组合物
BR0315056A (pt) 2002-11-01 2005-08-16 Pharmacia & Upjohn Co Llc Compostos tendo tanto atividade agonista nicotìnica de alfa7 quanto atividade antagonista de 5ht3 para o tratamento de doenças do sistema nervoso central
AU2003269413A1 (en) 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
AU2003279492A1 (en) 2002-12-11 2004-06-30 Pharmacia & Upjohn Company Llc Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
CA2509142A1 (en) 2002-12-11 2004-06-24 Pharmacia & Upjohn Company Llc Combination for the treatment of adhd
MXPA05007689A (es) 2003-01-22 2005-09-30 Pharmacia & Upjohn Co Llc Tratamiento de enfermedades con agonistas completos del receptor alfa-7 de nach.
US20070185079A1 (en) 2004-01-07 2007-08-09 Astrazeneca Ab Therapeutic agents I
JP5069108B2 (ja) 2004-07-21 2012-11-07 メルク セローノ ソシエテ アノニム オクタヒドロピロロ［２，３，ｃ］ピリジン誘導体と、その医薬としての利用法
DK1784404T3 (da) 2004-09-03 2012-02-13 Yuhan Corp Pyrrolo[2,3-c]pyridinderivater samt fremgangsmåder til deres fremstilling
JP5289769B2 (ja) 2004-12-08 2013-09-11 ヨハネス、グーテンベルク−ウニフェルジテート、マインツ ３−（インドリル）−４−アリールマレイミド誘導体および脈管形成阻害剤としてのそれらの使用
EP1838706A1 (en) 2004-12-24 2007-10-03 Prosidion Limited G-protein coupled receptor agonists
US7777035B2 (en) 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
US20070010523A1 (en) 2005-06-22 2007-01-11 Chemocentryx, Inc. Azaindazole compounds and methods of use
KR101142363B1 (ko) 2005-06-27 2012-05-21 주식회사유한양행 피롤로피리딘 유도체를 포함하는 항암제 조성물
CN101003537A (zh) 2006-01-17 2007-07-25 上海恒瑞医药有限公司 吡咯并哒嗪类衍生物及其制备方法和用途
GB0705803D0 (en) 2007-03-28 2007-05-02 Glaxo Group Ltd Novel compounds
NZ579892A (en) 2007-03-30 2012-03-30 Sanofi Aventis Pyrimidine hydrazide compounds as prostaglandin D synthase inhibitors
CA2683745A1 (en) 2007-04-16 2008-10-30 Merck & Co., Inc. Bicyclic anilide heterocyclic cgrp receptor antagonists
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
TWI443098B (zh) 2008-03-24 2014-07-01 Medivation Technologies Inc 吡啶并〔３，４－ｂ〕吲哚及使用方法
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
US8012992B2 (en) 2008-06-30 2011-09-06 Allergan, Inc. Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
DK2308877T3 (da) 2008-08-05 2014-04-22 Daiichi Sankyo Co Ltd Imidazopyridin-2-on-derivater
WO2010042337A1 (en) 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
EP2340243B1 (en) 2008-10-17 2014-10-08 Boehringer Ingelheim International GmbH Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
WO2010046780A2 (en) 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
AR074024A1 (es) 2008-11-14 2010-12-15 Merial Ltd Compuesto de arilazol-2-il-cianoetilamino enantiomericamente enriquecidos, composicion plaguicida y su uso para prevenir la infeccion parasitaria
WO2011096490A1 (ja) 2010-02-04 2011-08-11 第一三共株式会社 イミダゾピリジン－２－オン誘導体
JP2011178779A (ja) 2010-02-04 2011-09-15 Daiichi Sankyo Co Ltd イミダゾピリジン−２−オン誘導体
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
US9273028B2 (en) 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
CN103402996B (zh) 2011-01-04 2015-02-11 诺瓦提斯公司 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
EP2694509B1 (en) 2011-04-05 2016-05-18 Pfizer Limited Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of tropomyosin-related kinases
WO2012178022A2 (en) 2011-06-24 2012-12-27 University Of Massachusetts Therapeutic applications targeting sarm1
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
AR092289A1 (es) 2011-11-14 2015-04-15 Sunshine Lake Pharma Co Ltd Derivados de aminoquinazolina y sus sales y metodos de uso
CN102532027A (zh) 2012-03-01 2012-07-04 常州协丰医药研发有限公司 一种通过羟胺活化来形成吲唑衍生物的合成方法
CN102675310B (zh) 2012-05-09 2014-12-24 林辉 制备吡唑并芳杂环化合物的方法
US20150336948A1 (en) 2012-05-29 2015-11-26 Merck Sharp & Dohme Corp. Isotopically Labeled Biaryl Urea Compounds
JP6209605B2 (ja) 2012-06-28 2017-10-04 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
EP2867229B1 (en) 2012-06-28 2017-07-26 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
US9550755B2 (en) 2012-07-12 2017-01-24 Novartis Ag Complement pathway modulators and uses thereof
RU2611010C2 (ru) 2012-07-26 2017-02-17 Глаксо Груп Лимитед 2-(Азаиндол-2-ил)бензимидазолы в качестве ингибиторов PAD4
JP2016512543A (ja) 2013-03-12 2016-04-28 アッヴィ・インコーポレイテッド ジヒドロ−ピロロピリジノンブロモドメイン阻害剤
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
MD20150103A2 (ro) 2013-05-02 2016-02-29 Pfizer Inc. Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10
FR3008975A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3110419A4 (en) * 2014-02-25 2017-07-26 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of complement mediated disorders
JP6581111B2 (ja) 2014-04-28 2019-09-25 メッドシャイン ディスカバリー インコーポレイテッド Ｒｈｏキナーゼ阻害剤としてのイソキノリンスルホン誘導体
WO2015188368A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
US9708323B2 (en) 2014-06-13 2017-07-18 Bristol-Myers Squibb Company Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands
EP3154974B1 (en) 2014-06-13 2018-11-14 Bristol-Myers Squibb Company Tricyclic compounds as alpha- 7 nicotinic acetylcholine receptor ligands
EP3177630B1 (en) 2014-08-06 2019-10-23 California Institute of Technology Silylation of aromatic heterocycles by earth abundant transition-metal-free catalysts
EA033237B1 (ru) 2014-10-23 2019-09-30 Янссен Фармацевтика Нв Новые производные пиразолопиримидина в качестве ингибиторов nik, фармацевтическая композиция и лекарственное средство, содержащее ее
WO2016062792A1 (en) 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv New compounds as nik inhibitors
WO2016095089A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016095088A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
US9938276B2 (en) 2014-12-19 2018-04-10 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
WO2016161571A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Indazole and azaindazole btk inhibitors
US20180148429A1 (en) 2015-05-13 2018-05-31 Selvita S.A. Substituted quinoxaline derivatives
CA2988436A1 (en) 2015-07-13 2017-01-19 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
ES2821896T3 (es) 2015-08-05 2021-04-28 Indivior Uk Ltd Antagonistas del receptor de dopamina D3 que tienen una unidad estructural biciclo
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017106352A1 (en) 2015-12-14 2017-06-22 Raze Therapeutics, Inc. Caffeine inhibitors of mthfd2 and uses thereof
WO2017120429A1 (en) 2016-01-07 2017-07-13 CS Pharmasciences, Inc. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
TWI747873B (zh) 2016-02-01 2021-12-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
AU2017269726B2 (en) 2016-05-24 2021-10-14 Merck Patent Gmbh Tricyclic heterocylic derivatives
US20170355708A1 (en) 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators
EP4091622A1 (en) 2016-08-16 2022-11-23 Henry Ford Health System Compositions for the treatment of chemotherapy-induced neuropathic pain
AR109596A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos pirazolopiridina y sus usos
EP3515426A1 (en) 2016-09-24 2019-07-31 Washington University INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF
KR20190070972A (ko) 2016-11-02 2019-06-21 얀센 파마슈티카 엔.브이. Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 유도체
WO2018149986A1 (en) 2017-02-16 2018-08-23 Oryzon Genomics, S.A. 2-(bicyclo-heteroaryl)-isonicotinic derivatives as histone demethylase inhibitors
WO2018170165A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
DK3596053T3 (da) 2017-03-15 2023-09-25 Organovo Inc Farnesoid-x-receptoragonister og anvendelser deraf
WO2018170173A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2018210229A1 (zh) 2017-05-18 2018-11-22 南京明德新药研发股份有限公司 α-7尼古丁乙酰胆碱受体激动剂及应用
CN111278840B (zh) 2017-08-18 2023-11-17 癌症研究科技有限公司 吡咯并[2，3-b]吡啶化合物及其治疗癌症的用途
WO2019106087A1 (en) 2017-11-29 2019-06-06 Syddansk Universitet Ampk inhibitors
EP3717487B1 (en) 2017-12-01 2025-10-08 The Board of Trustees of the University of Illinois Pyridinone-based epigenetic modifiers and uses thereof
MX2020005841A (es) 2017-12-05 2020-09-07 Oryzon Genomics Sa Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.
CN112105357A (zh) 2018-02-16 2020-12-18 Ucb生物制药有限责任公司 药用6,5杂双环衍生物
TW201940483A (zh) 2018-03-12 2019-10-16 美商艾伯維有限公司 酪胺酸激酶２介導的傳訊之抑制劑
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
JP2019182784A (ja) 2018-04-10 2019-10-24 大日本住友製薬株式会社 ジヒドロピラゾロピラジノン誘導体
WO2019198024A1 (en) 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
US11882759B2 (en) 2018-04-13 2024-01-23 Universal Display Corporation Organic electroluminescent materials and devices
CN112384517B (zh) 2018-05-09 2023-07-14 新旭生技股份有限公司 杂芳基化合物及其用途
CA3102645A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
EP3801503A4 (en) 2018-06-07 2021-12-08 Disarm Therapeutics, Inc. INHIBITORS OF SARM1
CA3108676A1 (en) 2018-08-09 2020-02-13 David J. Guerin Carboxamides as ubiquitin-specific protease inhibitors

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080153828A1 (en) 2005-04-05 2008-06-26 Elizabeth Aaron Collins Imidazopyridazine Compounds
WO2009041567A1 (ja) 2007-09-27 2009-04-02 Banyu Pharmaceutical Co., Ltd. メラニン凝集ホルモン受容体拮抗作用を有するジアリールケチミン誘導体
JP2011530500A (ja) 2008-08-06 2011-12-22 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
JP2013519681A (ja) 2010-02-11 2013-05-30 オーエスアイ・ファーマシューティカルズ，エルエルシー ７−アミノフロピリジン誘導体
WO2012106343A2 (en) 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
JP2014509313A (ja) 2011-02-01 2014-04-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ７−アザインドール誘導体
WO2014198848A2 (en) 2013-06-12 2014-12-18 Lytix Biopharma As Compounds
WO2018011628A1 (en) 2016-07-11 2018-01-18 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2018071794A1 (en) 2016-10-14 2018-04-19 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Fisher, M. H. et al.，Azaindole anthelmintic agents，Journal of Medicinal Chemistry，1972年，Vol.15, No.11，pp.1168-1171
Gallou, Fet al.，Practical regioselective bromination of azaindoles and diazaindoles，Synlett，2007年，No.2，pp.211-214
REGISTRY[online]，2009.10.27-2012.7.23, [Retrieved on 2023.5.19], Retrieved from：STN, CAS登録番号 1190318-02-5、1384079-12-2

Also Published As

Publication number Publication date
CN112839648B (zh) 2025-04-04
US20220194933A1 (en) 2022-06-23
WO2019236884A1 (en) 2019-12-12
EP3801499B1 (en) 2024-02-28
CA3102598A1 (en) 2019-12-12
EP3801499A4 (en) 2022-01-12
ES2988933T3 (es) 2024-11-22
MA52809A (fr) 2021-04-14
US12448374B2 (en) 2025-10-21
JP2021528488A (ja) 2021-10-21
CN112839648A (zh) 2021-05-25
EP3801499A1 (en) 2021-04-14

Similar Documents

Publication Publication Date Title
JP7576145B2 (ja) Ｓａｒｍ１阻害剤
JP7659110B2 (ja) Ｓａｒｍ１の阻害剤
CN113966217B (zh) Sarm1抑制剂
JP7289375B2 (ja) Ｓａｒｍ１の阻害剤
JP7478252B2 (ja) Ｓａｒｍ１の阻害剤
US12448374B2 (en) Inhibitors of SARM1
JP7534390B2 (ja) Ｓａｒｍ１の阻害剤
JP7477642B2 (ja) Ｓａｒｍ１の阻害剤
JP7746384B2 (ja) Ｓａｒｍ１のベンゾピラゾール阻害剤
WO2020081923A1 (en) Inhibitors of sarm1 in combination with nad+ or a nad+ precursor
CA3102598C (en) Inhibitors of sarm1

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210409

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230530

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240419

R150 Certificate of patent or registration of utility model

Ref document number: 7478142

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150